Albemarle Posts Higher Year-Over-Year Revenue and Operating Income on Both Reported Windows, With Diluted EPS Shifting From Loss to Profit

Bottom line

- Albemarle Corporation (ticker ALB, CIK 0000915913) has filed the form designated 10-Q for fiscal period period-ended-2026-06-30 under accession 0000915913-26-000102, so the snapshot that follows is built only from that document. 52 per diluted share USD/SHARES. 87 per diluted share USD/SHARES.

- Compared with the prior-year three-month window the three months ended June 30, 2025, revenue moved higher, operating income moved higher, net income attributable to the parent moved higher, and diluted EPS shifted from a loss to a profit. - Compared with the prior-year six-month window the six months ended June 30, 2025, revenue moved higher, operating income moved higher, net income attributable to the parent moved higher, and diluted EPS shifted from a loss to a profit. - Management's only in-scope explanation in the source narrative is procedural: the unaudited statements are read together with the most recent annual report on the form designated 10-Q and reflect reclassifications to conform to the current presentation, per the cited basis-of-presentation note.

- The source narrative also describes the Refining Solutions Business Transaction (per the cited divestitures note), in which the Ketjen reportable segment was classified as held for sale at the prior year-end and closed in the current period, with the Company retaining an initial minority ownership interest in Holdco and the PCS business; the cited note states the divestitures were not treated as a discontinued operation. - The cited note on equity-method purchases and the cited fair-value hierarchy level do not appear in the source narrative excerpt provided for this section, so they are noted as present in the filing but not used to draw conclusions here.

- Analyst inference cannot add a driver for the year-over-year moves beyond the authorized direction and transition statements above; The filing evidence does not attribute this change to any single cause. applies to any further cause read. - Counter-evidence within the filing is limited to the held-for-sale caveat in the cited divestitures note, which constrains how the prior-period balance-sheet snapshot should be compared with current operations.

- No unknowns remain on the four financial lines for the two reported windows and their two prior-year comparatives; every fact cited above is grounded in the source record.

Financial performance

- For the three months ended June 30, 2026, ALBEMARLE CORP reported Revenues of $1,743,313,000 USD, reflecting an increase versus the prior-year the three months ended June 30, 2025 figure of $1,329,992,000 USD. For the broader the six months ended June 30, 2026 window, Revenues were $3,172,044,000 USD, higher than $2,406,873,000 USD for the six months ended June 30, 2025. - Operating Income (Loss) for the three months ended June 30, 2026 was $452,944,000 USD, an increase from $47,527,000 USD in the prior year, while the the six months ended June 30, 2026 result of $686,450,000 USD was higher than $67,288,000 USD for the six months ended June 30, 2025.

Both windows remain in profit on a year-over-year basis. - Net Income (Loss) Attributable to Parent came in at $479,959,000 USD for the three months ended June 30, 2026 and $799,050,000 USD for the six months ended June 30, 2026, each greater than the prior-year comparables of $22,897,000 USD and $64,245,000 USD, respectively, with both reporting periods remaining profitable. 87 per diluted share USD/SHARES for the six months ended June 30, 2026.

16 per diluted share USD/SHARES, respectively, marking a transition from loss to profit. - The accounting context in Note 2 explains that the Ketjen-related Refining Solutions business met held-for-sale criteria at the prior balance-sheet date, with assets and liabilities segregated on the consolidated balance sheet at that point. Management noted that the Refining Solutions sales did not qualify for discontinued-operations treatment because they were not considered a strategic shift that had or will have a major effect on operations and financial results, so the results flow through continuing operations in the the three months ended June 30, 2026 and the six months ended June 30, 2026 numbers above.

- Note 8 describes the equity structure of the Company, including its retained ownership interest in the Ketjen joint venture following the Refining Solutions Business Transaction, which is valued using a Black-Scholes option-pricing model and is classified as Level 3 within the fair-value hierarchy due to unobservable inputs. That valuation flow can affect equity-method income and the carrying value of Investments, but no separate, identifiable amount is disclosed in the claim set. - The Company also purchases inventory from its equity-method investees, primarily the Windfield joint venture, eliminating intra-entity profit on unsold inventory and recognizing it only when that inventory is sold to a third-party customer in the same period; this affects Cost of goods sold and Equity in net income of unconsolidated investments (net of tax) without producing a separately quantified line item in the claims above.

- Management does not provide a quantitative forward outlook for Revenues, Operating Income, Net Income, or Diluted EPS in the cited notes, so guidance, expectations, and the size of any sequential move cannot be derived from the filing evidence. The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison, so no external benchmark against other lithium, bromine, or catalysts producers can be supported in this section.

The filing evidence contains no peer or industry comparison. - For a cross-issuer look at how other reporters described their most recent interim windows, see C&F Financial Posts Higher Year-Over-Year Revenue, Net Income, and Diluted EPS on Both Reported Windows in, which contrasts with the issuer's loss-to-profit EPS transition on the same comparative basis.

Operating drivers and segments

- Revenues for the six months ended June 30, 2026 were $3,172,044,000 USD, an authorized increase relative to the prior-year comparative of $2,406,873,000 USD for the six months ended June 30, 2025. - Revenues for the three months ended June 30, 2026 were $1,743,313,000 USD, an authorized increase relative to the prior-year comparative of $1,329,992,000 USD for the three months ended June 30, 2025. - Operating Income (Loss) for the six months ended June 30, 2026 was $686,450,000 USD, an authorized increase versus $67,288,000 USD for the six months ended June 30, 2025, with an authorized transition profit to profit. - Operating Income (Loss) for the three months ended June 30, 2026 was $452,944,000 USD, an authorized increase versus $47,527,000 USD for the three months ended June 30, 2025, with an authorized transition profit to profit. - Management frames the period segment composition through the Refining Solutions divestiture, treated by ALBEMARLE CORP as the Ketjen reportable segment excluding the PCS business and the Company's interest in Eurecat S.A., per the cited note. - For the quarter and half-year views, Revenues and Operating Income (Loss) both moved in the authorized increase direction; no segment-level split is cited in the filing evidence.

- Management's narrative centers on the Refining Solutions Business Transaction, in which the Company signed a definitive agreement in October (omitted) to divest the controlling ownership interest of its Refining Solutions business to ChemCat AcquisitionCo, LLC and contribute the remaining interest to ChemCat Holdings, LP, with closing in March (omitted), per the cited note. - The Company retained common units of Holdco and the PCS business following closing, with the Holdco interest initially representing a (omitted) stake. - The transaction consideration, as disclosed, comprised cash, net of cash sold, plus common units in Holdco, while the Eurecat S.A. investment was excluded from the divestiture. - Refining Solutions was classified as held for sale and measured at the lower of carrying amount or fair value less costs to sell, and the assets and liabilities held for sale were presented in the December (omitted) consolidated balance sheet. - Management concluded the divestiture did not qualify for discontinued operations treatment at December (omitted), because it was not considered a strategic shift with a major effect on operations and financial results. - Inventory purchases from equity method investments, primarily the Windfield Holdings Pty. joint venture, are intra-entity eliminated against Equity in net income of unconsolidated investments (net of tax), per the cited note. - Management does not, in the filing evidence, attribute the year-over-year movements in Revenues or Operating Income (Loss) to any specific segment driver beyond the divestiture context.

The filing evidence does not attribute this change to any single cause.

Independent analyst view versus management framing:

- The filing evidence confirms the authorized directional increases in Revenues and Operating Income (Loss) on both reported windows, but does not provide a segment-level decomposition across Energy Storage, Specialties, or Ketjen; therefore segment margin drivers cannot be independently isolated from this filing. - The Refining Solutions transaction removed a piece of the Ketjen reportable segment, so prior-year segment comparisons on a continuing-operations basis are not directly available from the cited note; management instead frames the change as a divestiture rather than a discontinued operation. - The retention of Holdco common units and the PCS business means part of the former Refining Solutions economic exposure persists within ALBEMARLE CORP's structure, which an analyst should weigh when interpreting subsequent-period segment results. - The intra-entity profit elimination on Windfield-related inventory remains a recurring technical adjustment that affects Equity in net income of unconsolidated investments rather than Revenues or Operating Income (Loss) directly. - The filing evidence contains no peer or industry comparison. - Counter-evidence searches in the filing for an explicit volume-versus-price bridge, an energy-storage contract update, or a lithium price reference that would independently corroborate the authorized directional increases were not found; the narrative remains anchored to the divestiture and reclassification footnotes. - Readers comparing this window to other period-ended interim filings, such as C&F Financial Posts Higher Year-Over-Year Revenue, Net Income, and Diluted EPS on Both Reported Windows in, should note that the directional pattern is consistent but the underlying segment mix is not directly comparable.

Cash flow and capital

- The current-year six-month cash flow statements show operating activities were a source of funds at $1,056,241,000, while the prior-year comparative period recorded a smaller inflow at $538,180,000. The authorized comparison confirms operating cash generation improved year over year. - Investing activities were a use of funds in the current six-month period at $460,520,000, against an inflow in the prior-year comparative at $183,612,000.

The authorized comparison shows a larger net outflow this year, consistent with stepped-up capital deployment rather than last year's net divestiture-related inflow. - Financing activities were a use of funds in both periods: -$1,493,406,000 for the current six months versus -$210,640,000 for the prior-year comparative. The authorized comparison confirms a deeper outflow this year, indicating heavier repayments, lower net borrowings, or both, relative to last year.

- Capital expenditures, reported as Payments to Acquire Property, Plant, and Equipment, were $170,407,000 in the current six-month period versus $302,252,000 in the prior-year comparative. The authorized comparison shows a year-over-year decline in spending on property, plant, and equipment, despite investing cash flow appearing heavier — which suggests the investing-line deterioration is not driven by capex alone. The filing evidence does not attribute this change to any single cause.

- Ordinary common-stock dividend payments were $95,372,000 for the current six months versus $95,244,000 for the prior-year comparative, with the authorized comparison indicating higher cash returned to common shareholders through dividends this year. - On the balance sheet at the balance sheet date of June 30, 2026, the company reported Cash and Cash Equivalents of $1,631,688,000, Accounts Receivable (after the credit-loss allowance) of $603,805,000, and Long-term Debt excluding current maturities of $1,802,107,000.

The combination of a meaningful long-term debt balance alongside operating cash generation frames the capital allocation trade-off between funding capex and continued dividend distributions. - Liquidity is also supported by an off-balance-sheet facility: the company is party to master receivables purchase agreements allowing the sale of up to a publicly cited cap of customer receivables at any one time. Under those agreements, the company removed receivables from the consolidated balance sheets during the three-month and six-month periods ended in June, incurring associated fees that flow through the income statement.

The cited note confirms these transactions are accounted for as true sales rather than as borrowings. - Capital allocation priorities observable from the statement of cash flows therefore lean toward continued dividend returns and balance-sheet management, with capex trimmed year over year and the investing line reflecting a wider net outflow that is not fully explained by the lower capex figure. The filing evidence does not attribute this change to any single cause.

- The filing does not disclose segment-level capital spending or a peer benchmark for any of these dimensions. The filing evidence does not disclose segment-level detail for this dimension. The filing evidence contains no peer or industry comparison.

Peer and historical context

Readers evaluating ALBEMARLE CORP (ALB) through the lens of period-ended-2026-06-30 under 10-Q can only walk one comparison hallway with the filing evidence: the company's own prior-year windows. Like peers at the same filing cadence — see how a different issuer handled a similar comparison window in C&F Financial Posts Higher Year-Over-Year Revenue, Net Income, and Diluted EPS on Both Reported Windows and UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows — the relevant comparison for ALBEMARLE CORP is half-year to half-year and quarter to quarter, not quarter to half-year.

On the six-month window, both top-line and bottom-line tracked higher than the prior-year comparative: Revenues moved from $2,406,873,000 to $3,172,044,000 (direction increase), Operating Income moved from $67,288,000 to $686,450,000 (profit to profit, direction increase), Net Income Attributable to Parent moved from $64,245,000 to $799,050,000 (profit to profit, direction increase), and Net Cash Provided by Operating Activities moved from $538,180,000 to $1,056,241,000 (direction increase). All four stepped up in the same direction across the year-to-date window, with no sign reversal.

On the three-month window, the trajectory is the same in shape: Revenues moved from $1,329,992,000 to $1,743,313,000 (direction increase), Operating Income moved from $47,527,000 to $452,944,000 (profit to profit, direction increase), and Net Income Attributable to Parent moved from $22,897,000 to $479,959,000 (profit to profit, direction increase). Operating cash flow for the comparable half-year window also climbed, though standalone operating cash flow for the quarterly-only window is not separately tracked in the catalog.

Peer benchmarking against lithium, catalyst, or broader specialty-chemicals names is not available inside the filing — the catalog carries no S-curve of competing issuers. The filing evidence contains no peer or industry comparison. On the company's own historical record, however, the picture is consistent across every catalogued line item: both reported windows are positive, both reported windows moved up versus their prior-year comparatives, and there is no transition in sign anywhere in the set. That is a single, internally coherent direction across revenue, operating result, reported earnings, and operating cash generation.

- Set against only its own prior year, ALBEMARLE CORP shows a uniform year-over-year step-up on revenue, operating income, net income, and operating cash for the half-year window, and a parallel step-up on revenue, operating income, and net income for the quarter-only window. - Because the comparison shelf in the filing is purely internal historical, no read-across to peers, end markets, or competing filings is justified from this evidence alone.

- A change uniform across all catalogued line items can mask very different magnitudes; the qualitative direction "increase" leaves the size of each gap undisclosed in the prose, so the conclusion that the half-year lift mirrors the quarter lift is unsupported. - Compared with filings like C&F Financial Posts Higher Year-Over-Year Revenue, Net Income, and Diluted EPS on Both Reported Windows, ALBEMARLE CORP adds the operating-cash-flow signal alongside the three P&L lines; whether that broader spread is a stronger indicator cannot be quantified from the catalog. - For the quarter-only window, operating cash flow is not catalogued, so the "uniform direction" claim applies only to revenue and the two P&L lines, not to all four items. The filing evidence does not attribute this change to any single cause.

Scenario analysis

- A continuation of the current growth path, where $3,172,044,000 and $1,743,313,000 remain in an upward year-over-year direction versus the prior comparatives $2,406,873,000 and $1,329,992,000, paired with $799,050,000 and $479,959,000 holding above $64,245,000 and $22,897,000 on a profit-to-profit basis, is the central anchor for the base case in the the six months ended June 30, 2026 and the three months ended June 30, 2026 windows. - Reported figures (not analyst estimates) drawn from 10-Q for period-ended-2026-06-30 under 0000915913-26-000102 are the only inputs treated as evidence; outside peer benchmarks are not in scope, so The filing evidence contains no peer or industry comparison. is the operative caveat. - The non-cash swing from public-equity mark-to-market activity — disclosed as both unrealized gains in one reading and unrealized gains/(losses) in another — is treated as a normal-course item rather than a recurring driver, with attribution left to The filing evidence does not attribute this change to any single cause. where any single cause would otherwise need to be named. - One-off preferred-equity issuance economics tied to the referenced Grace subsidiary, and the customer-funded multi-year spodumene/lithium-salt advance tied to deferred revenue, are flagged as non-recurring items whose future repetition is not assumed under the base path.

- A constructive path would see $3,172,044,000 and $1,743,313,000 extend their positive direction versus $2,406,873,000 and $1,329,992,000 alongside $799,050,000 and $479,959,000 widening their positive gap over $64,245,000 and $22,897,000 on a profit-to-profit basis. - The deferred-revenue prepayment of spodumene and lithium salts referenced in the cited note Note 2 could provide forward revenue visibility across the next several years, though the magnitude and timing are not stated numerically in the filing, and no peer comparison is available, so The filing evidence contains no peer or industry comparison. applies. - Continued mark-to-market favorability on public-equity holdings, as referenced in Note 8, would support the upside narrative; the machine-owned causality line The filing evidence does not attribute this change to any single cause. governs any single-cause attribution. - Receivables-facility capacity referenced in Item 1A provides optional liquidity, but its future draw is not modeled here.

- A weaker path would see $3,172,044,000 and $1,743,313,000 flattening against $2,406,873,000 and $1,329,992,000 or moving below them, and $799,050,000 and $479,959,000 compressing toward — but still remaining positive relative to — $64,245,000 and $22,897,000. - The cited note Note 8 highlights unrealized gains (losses) on public equity that could reverse, which under the downside would be the principal earnings-sensitivity item; any single-cause framing is again deferred to The filing evidence does not attribute this change to any single cause.. - The Grace-related preferred-equity fair-value differential and the multi-year deferred-revenue delivery commitment tied to specified amounts of spodumene and lithium salts would, in a stress reading, expose margin risk if market conditions weaken; the magnitude is not numerically disclosed in the catalog, and no peer comparison is available (The filing evidence contains no peer or industry comparison.). - For context on how another interim filer framed softer top-line outcomes, see DATA I/O CORP Reports Wider Losses on Softer Revenue in Latest Interim Filing.

Risks and what to watch

Reported facts in this filing offer a narrow window into risk: revenue and net income are visible on both the the three months ended June 30, 2026 and the six months ended June 30, 2026 windows, alongside their prior-year comparatives, but the surrounding disclosures are unusually thin. The risk-factor section itself (the section labeled for material risk updates) carries an "Item not applicable" or substitute marker in the source narrative, which means readers should not assume the prior risk-factor inventory has been refreshed in this filing.

Management explanations inside the quoted material point to two working-capital and contract items worth flagging. First, the master receivables purchase agreements allow the ALBEMARLE CORP to sell up to a stated cap of eligible customer receivables at any time; these arrangements are uncommitted and terminable on notice, so reported revenue during the three months ended June 30, 2026 and the six months ended June 30, 2026 ($1,743,313,000 and $3,172,044,000, each compared against $1,329,992,000 and $2,406,873,000) reflects a receivables-sale program whose capacity could shift quickly. Second, the deferred-revenue disclosure records an advance payment from a customer covering specified spodumene and lithium salts deliveries over a multi-year window, tying future revenue recognition to contract performance rather than spot pricing. The filing evidence does not attribute this change to any single cause.

Counter-evidence to the headline profit story is limited in this filing. Net income attributable to parent is positive on both reported windows — $479,959,000 versus $22,897,000, and $799,050,000 versus $64,245,000 — and operating income, diluted EPS, financing and investing cash flows, dividends, and capex all carry authorized year-over-year directives, but the cited notes do not isolate lithium pricing, energy cost, or currency effects within these figures. The fair-value context (Level 3) signals reliance on unobservable inputs for certain measurements, and the equity disclosure (Note 8) and divestiture disclosure (Note 2) appear in passing rather than as a quantified driver analysis.

Unknowns the reader should carry forward: no peer or industry margin benchmark is provided here, segment-level revenue and margin detail is not disclosed in the quoted excerpt, and the link between the receivables program and any stated liquidity target is not spelled out by management. The reader-facing finance context for interpreting revenue swings across reporting periods is broadly covered in the Lizely Finance Earnings Analysis library, which helps frame — but cannot resolve — the open items above.

Key metrics to watch next period: the cap on the master receivables purchase program and the volume actually sold during the next quarter; the rate of release of the deferred-revenue balance tied to the multi-year spodumene and lithium salts contract; any refresh of risk factors in Item 1A; and any quantified segment data that would let readers reconcile revenue ($1,743,313,000, $3,172,044,000) against profit ($479,959,000, $799,050,000) by business line.